Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026)

Viatris' (VTRS) quarterly Non-Current Deferred Tax Liability came in at $870.6 million in Q1 2026, down 19.58% year-on-year from $1.1 billion in Q1 2025, and down 2.4% quarter-over-quarter from $892.0 million in Q4 2025.

Viatris (VTRS) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends

Viatris' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $870.6 million for Q1 2026.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 19.58% year-over-year to $870.6 million in Q1 2026; TTM through Mar 2026 was $870.6 million, a 19.58% decrease from a year earlier, with the FY2025 full-year figure at $892.0 million, down 55.55% from the prior year.
  • Non-Current Deferred Tax Liability retreated to $870.6 million in Q1 2026 per VTRS's latest filing, from $892.0 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $2.7 billion in Q1 2022 and bottomed at $870.6 million in Q1 2026.
  • The 5-year median for Non-Current Deferred Tax Liability is $1.7 billion (2023), against an average of $1.8 billion.
  • Across the five-year window, Non-Current Deferred Tax Liability increased 15.62% in 2024 and tumbled 55.55% in 2025, its largest moves.
  • Year by year, Non-Current Deferred Tax Liability stood at $2.4 billion in 2022, then decreased by 28.63% to $1.7 billion in 2023, then advanced by 15.62% to $2.0 billion in 2024, then tumbled by 55.55% to $892.0 million in 2025, then fell by 2.4% to $870.6 million in 2026.
  • Per Business Quant, the three latest VTRS Non-Current Deferred Tax Liability figures stand at $870.6 million (Q1 2026), $892.0 million (Q4 2025), and $1.0 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 870.60 Mn
Mar 31, 2026 870.60 Mn
Dec 31, 2025 892.00 Mn
Dec 31, 2025 892.00 Mn
Sep 30, 2025 1.03 Bn
Sep 30, 2025 1.03 Bn
Jun 30, 2025 1.08 Bn
Jun 30, 2025 1.08 Bn
Mar 31, 2025 1.08 Bn
Mar 31, 2025 1.08 Bn
Dec 31, 2024 2.01 Bn
Dec 31, 2024 2.01 Bn
Sep 30, 2024 1.28 Bn
Sep 30, 2024 1.28 Bn
Jun 30, 2024 1.57 Bn
Jun 30, 2024 1.57 Bn
Mar 31, 2024 1.67 Bn
Mar 31, 2024 1.67 Bn
Dec 31, 2023 1.74 Bn
Dec 31, 2023 1.74 Bn